638 related articles for article (PubMed ID: 30075835)
1. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
[TBL] [Abstract][Full Text] [Related]
4. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy.
De Mattia E; Bignucolo A; Toffoli G; Cecchin E
Curr Med Chem; 2020; 27(25):4249-4273. PubMed ID: 31298142
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.
Bignucolo A; De Mattia E; Cecchin E; Roncato R; Toffoli G
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28708103
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Madi A; Fisher D; Maughan TS; Colley JP; Meade AM; Maynard J; Humphreys V; Wasan H; Adams RA; Idziaszczyk S; Harris R; Kaplan RS; Cheadle JP
Eur J Cancer; 2018 Oct; 102():31-39. PubMed ID: 30114658
[TBL] [Abstract][Full Text] [Related]
7. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
Panczyk M
World J Gastroenterol; 2014 Aug; 20(29):9775-827. PubMed ID: 25110414
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.
Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM
Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments.
Bruera G; Ricevuto E;
Pharmgenomics Pers Med; 2020; 13():601-617. PubMed ID: 33235483
[TBL] [Abstract][Full Text] [Related]
12. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Tan BR; McLeod HL
Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
[TBL] [Abstract][Full Text] [Related]
16. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
[No Abstract] [Full Text] [Related]
17. Pharmacogenomics and Personalized Medicine.
Cecchin E; Stocco G
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients.
Qin W; Du Z; Xiao J; Duan H; Shu Q; Li H
Pharmacogenomics; 2020 Feb; 21(3):209-219. PubMed ID: 31967514
[No Abstract] [Full Text] [Related]
19. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
Cortejoso L; López-Fernández LA
Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
[TBL] [Abstract][Full Text] [Related]
20. Genetic markers in methotrexate treatments.
Giletti A; Esperon P
Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
